Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ropivacaine liposomal - Taiwan Liposome Company

Next Previous
Drug Profile

Ropivacaine liposomal - Taiwan Liposome Company

Alternative Names: TLC-590

Latest Information Update: 22 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiwan Liposome Company
  • Class Alkanes; Amides; Anilides; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules; Xylenes
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 17 Nov 2025 Phase-III clinical trials in Postoperative pain in USA (Parenteral) (NCT07222748)
  • 30 Oct 2025 TLC Biopharmaceuticals plans a phase III trial for Postoperative Pain in the US, in November 2025 (Extended-Release Injectable Suspension) (NCT07222748)
  • 27 Aug 2024 Taiwan Liposome Company plans a phase II trial for post-operative pain in the US (Controlled release) (NCT06574269)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top